SWOG clinical trial number
CTSU/E1302
Phase III Randomized, Placebo-Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer
Closed
Phase
Abbreviated Title
Phase III Randomized, Placebo-Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head…
Activated
07/15/2006
Closed
01/10/2007
Participants
CTSU
Research committees
Head and Neck Cancer
Treatment
Docetaxel
ZD1839
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.